UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 27, 2016
EXACT SCIENCES CORPORATION
(Exact Name of Registrant as Specified in Charter)
|
Delaware |
|
001-35092 |
|
02-0478229 |
|
(State or Other Jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
5601 Research Park Drive
Madison, WI 53711
(Address of Principal Executive Offices)(Zip Code)
Registrant’s telephone number, including area code: (608) 284-5700
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement.
On July 27, 2016, Exact Sciences Corporation (the “Company,” “we,” “us” and “our”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC and Robert W. Baird & Co. Incorporated (the “Underwriters”), as representatives of the several underwriters named therein, relating to the issuance and sale of 8,500,000 shares of the Company’s common stock, par value $0.01 per share. On July 28, 2016, pursuant to the terms of the Underwriting Agreement, the Underwriters exercised their option to purchase an additional 1,275,000 shares of common stock (the “Optional Shares”). The net proceeds to us from this offering, including proceeds from the sale of the Optional Shares, are expected to be approximately $144.5 million, after deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on or about August 2, 2016, subject to customary closing conditions.
The offering is being made pursuant to our effective registration statement on Form S-3 (Registration Statement No. 333-212701) previously filed with the Securities and Exchange Commission and a prospectus supplement thereunder. The Underwriting Agreement is filed as Exhibit 1 to this report, and the description of the terms of the Underwriting Agreement is qualified in its entirety by reference to such exhibit. A copy of the opinion of K&L Gates LLP relating to the legality of the issuance and sale of the shares in the offering is attached as Exhibit 5 hereto.
On July 27 and July 28, 2016, we issued press releases with respect to the offering. These press releases are attached as Exhibit 99.1 and Exhibit 99.2 hereto, respectively.
Item 9.01. Financial Statements and Exhibits.
Exhibits
The exhibits required to be filed as a part of this Current Report on Form 8-K are listed in the Exhibit Index attached hereto and incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
EXACT SCIENCES CORPORATION | |
|
|
| |
|
Date: August 1, 2016 |
By: |
/s/ John Bakewell |
|
|
John Bakewell | |
|
|
Chief Financial Officer | |